View Older Stories View More Recent Stories

Jun 9, 2021 07:15AM ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma
Jun 4, 2021 01:52PM ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting
May 27, 2021 07:15AM ADC Therapeutics to Present at Jefferies Virtual Healthcare Conference
May 26, 2021 07:16AM ADC Therapeutics SA (ADCT) Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology
May 26, 2021 07:15AM ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology
May 19, 2021 06:15PM ADC Therapeutics Announces Presentations at the 2021 ASCO Annual Meeting
May 17, 2021 07:15AM ADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield
May 12, 2021 07:22AM ADC Therapeutics SA (ADCT) Reports Publication of LOTIS-2 Results
May 12, 2021 07:15AM ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology
May 6, 2021 07:00AM ADC Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
May 5, 2021 07:14PM ADC Therapeutics’ ZYNLONTA™ (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for B-cell Lymphomas
May 4, 2021 07:15AM ADC Therapeutics to Participate in May Investor Conferences
Apr 29, 2021 07:15AM ADC Therapeutics to Host First Quarter 2021 Financial Results Conference Call on May 6, 2021
Apr 23, 2021 02:38PM ADC Therapeutics SA (ADCT) Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Apr 23, 2021 02:38PM ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Apr 6, 2021 07:04AM Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer (ADCT)
Apr 6, 2021 07:00AM Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer
Mar 18, 2021 07:00AM ADC Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Updates
Mar 11, 2021 07:15AM  ADC Therapeutics to Host Fourth Quarter and Year-End 2020 Financial Results Conference Call on March 18, 2021
Feb 25, 2021 07:15AM ADC Therapeutics to Participate in Cowen 41st Annual Health Care Conference
Feb 5, 2021 07:15AM ADC Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Day
Feb 4, 2021 07:21AM ADC Therapeutics SA (ADCT) Reports Complete Enrollment in Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in R/R Hodgkin Lymphoma
Feb 4, 2021 07:15AM ADC Therapeutics Completes Enrollment in Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
Jan 7, 2021 07:15AM ADC Therapeutics Initiates Expanded Access Program for Loncastuximab Tesirine in the U.S.
Jan 4, 2021 07:15AM ADC Therapeutics to Participate in SternIR Virtual Corporate Access Event
Dec 14, 2020 07:00AM ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater Chi
Dec 7, 2020 07:11AM ADC Therapeutics SA (ADCT) Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at ASH
Dec 7, 2020 07:00AM ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematolo
Nov 30, 2020 07:15AM ADC Therapeutics to Host Conference Call Highlighting Data from its Next-Generation Antibody Drug Conjugates Being Presented at the 62nd American Society of Hematology Annual Meeting
Nov 20, 2020 07:03AM ADC Therapeutics SA (ADCT) Announces FDA Accepts BLA and Grants Priority Review for Loncastuximab Tesirine for Treatment of R/R Diffuse Large B-cell Lymphoma
Nov 20, 2020 07:00AM ADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Nov 12, 2020 07:00AM ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business Highlights
Nov 10, 2020 07:15AM ADC Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
Nov 5, 2020 07:15AM ADC Therapeutics to Host Third Quarter 2020 Financial Results Conference Call on November 12, 2020
Nov 4, 2020 11:00AM ADC Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual Meeting
Nov 3, 2020 07:23AM ADC Therapeutics SA (ADCT) Reports First Patient Dosed with Camidanlumab Tesirine in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid Tumors
Nov 3, 2020 07:15AM ADC Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid Tumors
Oct 30, 2020 07:17AM Genmab A/S (GMAB), ADC Therapeutics (ADCT) Announce Amended Agreement for Camidanlumab Tesirine
Oct 30, 2020 07:15AM Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
Oct 30, 2020 07:15AM Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
Sep 21, 2020 04:07PM ADC Therapeutics (ADCT) Submits BLA to FDA for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sep 21, 2020 04:05PM ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sep 17, 2020 07:17AM ADC Therapeutics (ADCT) Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine in Advanced Solid Tumors at ESMO
Sep 17, 2020 07:15AM ADC Therapeutics Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine (Cami) in Advanced Solid Tumors at ESMO Virtual Congress 2020
Sep 10, 2020 07:37AM ADC Therapeutics SA (ADCT) Reports Publication Highlighting Potential of Camidanlumab Tesirine as Novel Immuno-oncology Approach for Solid Tumor Cancers
Sep 10, 2020 07:35AM ADC Therapeutics Announces Publication Highlighting the Potential of Camidanlumab Tesirine (Cami) as a Novel Immuno-oncology Approach for Solid Tumor Cancers
Sep 4, 2020 09:30PM ADC Therapeutics Gives Notice of Partial Waiver of Restrictions Pursuant to FINRA Rule 5131
Aug 18, 2020 07:15AM ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business Highlights
Aug 12, 2020 04:15PM ADC Therapeutics to Report Second Quarter 2020 Financial Results on August 18, 2020
Jul 17, 2020 07:30AM ADC Therapeutics SA (ADCT) Reports First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With Ibrutinib
View More Recent Stories View Older Stories